Biosimilar Market Size, Growth, Analysis and Forecast 2016 by Radiant Insights

Biosimilar Market Size, Share, Analysis and Forecast 2016 by

Radiant Insights

Synopsis

Responding to strong desire of overseas and multinational pharmaceutical manufacturers and domestic

pharmaceutical manufacturers to carry out research and development of biosimilar products, this is first time in

history, Chinese pharmaceutical authorities, China Food and Drug Administration officially issued a technical

guidance for development and evaluation of biosimilars and defined the pathway of license approval for

biosimilars. Chinese pharmaceutical authorities require that when conducting the research and development of

biosimilar products in China, the applicant of biosimilar registration application and its sponsor should be in

compliance with the Guidance and follow the pathway of license approval of biosimilars.

How to grasp the opportunity to smoothly conduct the research and development of biosimilar products in China

and speed up your biosimilar product approval time? The overseas and multinational pharmaceutical

manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and

thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars,

Browse Complete Summary, Click Here @ http://www.radiantinsights.com/research/latest-chinese-guidancefor-development-evaluation-license-approval-of-biosimilars

Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive

and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of

biosimilars and guide you use the Chinese trial venues to keep biosimilars development lean and to smoothly

operate in China.

Summary

China has an indispensable biosimilar market for overseas and multinational pharmaceutical companies. Historical

data shows 40 per cent of China's $1.5bn recombinant biologic product sales come from biosimilars, which...